In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)

Recent Patents on Anti-Cancer Drug Discovery

Volumn 5, Issue 1, 2010, Pages 58-68

  Marfe, Gabriella ^a   Di Stefano, Carla ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Accelerated phase; Apoptosis; Bax; BCR ABL protein; Bcr Abl dependent mechanisms; Caspase 3; Caspase 8; Caspase 9; Chronic myelogenous leukemia; Dasatinib; DNA fragmentation; Imatinib; Nilotinib; Pyrrolo 1,2b 1,2,5 benzothiadiazepine 5,5 dioxides; Tyrosine kinase inhibitors

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; BENZODIAZEPINE DERIVATIVE; CASPASE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DORAMAPIMOD; IMATINIB; NILOTINIB; PYRROLO[1,2 B][1,2,5]BENZOTHIADIAZEPINE DERIVATIVE; SGX 70430; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; THIAZEPINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; REVIEW; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; THIAZEPINES;

EID: 77649240586     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489210789702163     Document Type: Article

References (114)

1. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenousleukemia: Biology and therapy. Ann Intern Med 1999; 131:207-219.
2. Goldman JM, Melo JV. Chronic myeloid leukemia advances inbiology and new approaches to treatment. N Engl J Med 2003; 349:1451-1464.
3. Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia inbcr/abl transgenic mice. Nature 1990; 344: 251-253.
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronicmyelogenous leukemia in mice by the P210bcr/abl gene of thePhiladelphia chromosome. Science 1990; 247: 824-830.
5. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of achronic myelogenous leukemia-like myeloproliferative disease inmice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92: 3780-3792
6. Maekawa T, Ashihara E, Kimura S. The BCR-ABL tyrosine kinaseinhibitor imatinib and promising new agents against Philadelphiachromosome-positive leukemias. Int J Clin Oncol 2007; 12: 327-340.
7. Herr I, Debatin KM. Cellular stress response and apoptosis incancer therapy. Blood 2001; 98: 2603-2614.
8. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-776.
9. Rich T, Allen RL, Wyllie AH. 2000. Defying death after DNAdamage. Nature 2000; 407: 777-783.
10. Karin M, Cao Y, Greten FR, Li ZW. NF-Kappab in cancer: Frominnocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
11. Davis RJ. Signal transduction by the JNK group of MAP kinases.Cell 2000; 103: 239-252.
12. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
13. Igney FH, Krammer PH. Death and anti-death: Tumour resistanceto apoptosis. Nat Rev Cancer 2002; 2: 277-288.
14. Leist M, Jaattela M. Four deaths and a funeral: From caspases toalternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-598.
15. Van Etten RA. c-Abl regulation: A tail of two lipids. Curr Biol 2003; 13: R608-R610.
16. Smith KM, Yacobi R, Van Etten RA Autoinhibition of Bcr-Ablthrough its SH3 domain. Mol Cell 2003; 12: 27-37.
17. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Ablprotein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
18. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanismfor STI-571 inhibition of abelson tyrosine kinase. Science 2000;289: 1938-1942.
19. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition ofthe Abl kinase activity blocks the proliferation of Bcr- Abl+leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23: 380-394.
20. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosinekinase inhibitor CGP57148B selectively inhibits the growth of Bcr-Abl-positive cells. Blood 1997; 90: 3691-3698.
21. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selectiveinhibitor of the Abl tyrosine kinase on the growth of Bcr-Ablpositive cells. Nat Med 1996; 2: 561-566.
22. Koldehoff M, Elmaagacli AH. Therapeutic targeting of geneexpression by siRNAs directed against BCR-ABL transcripts in apatient with imatinib-resistant chronic myeloid leukemia. MethodsMol Biol 2009; 487: 451-466.
23. Druker BJ, Guilhot F, O'Brien SG, et al. IRIS Investigators. Fiveyearfollow-up of patients receiving imatinib for chronic myeloidleukemia. N Engl J Med 2006; 355: 2408-2417.
24. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specificinhibitor of the BCR-ABL tyrosine kinase in the blast crisis ofchronic myeloid leukemia and acute lymphoblastic leukemia withthe Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
25. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenousleukemia: Strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-1331.
26. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinasedomain mutations confer polyclonal resistance to the tyrosinekinase inhibitor imatinib (STI571) in chronic phase and blast crisischronic myeloid leukemia. Cancer Cell 2002: 2: 117-125.
27. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance toSTI-571 cancer therapy caused by BCR-ABL gene mutation oramplification. Science 2001; 293: 876-880.
28. Lowenberg B. Minimal residual disease in chronic myeloidleukemia. N Engl J Med 2003; 349: 1399-1401.
29. Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW.Several BCR-ABL kinase domain mutants associated with imatinibmesylate resistance remain sensitive to imatinib. Blood 2003; 101:4611-4614.
30. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecularmechanisms of resistance to imatinib in Philadelphia chromosomepositiveleukaemias. Lancet Oncol 2003; 4: 75-85.
31. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanismfor STI-571 inhibition of abelson tyrosine kinase. Science 2000;289: 1938-1942.
32. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures ofthe kinase domain of c-Abl in complex with the small moleculeinhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62:4236-4243.
33. Hantschel O, Nagar B, Guettler S, et al. A myristoyl/phosphotyrosines witch regulates c-Abl. Cell 2003; 112: 845-857.
34. Verma D, Fava C, Kantarjian H, Cortes J. Complexity of BCRABLkinase domain mutations during the course of therapy withtyrosine kinase inhibitors in chronic myeloid leukemia. Am JHematol 2009; 84: 256-257.
35. Lee TS, Ma W, Zhang X, et al. BCR-ABL alternative splicing as acommon mechanism for imatinib resistance: Evidence frommolecular dynamics simulations. Mol Cancer Ther 2008; 7: 3834-3841.
36. Okabe S, Tauchi T, Ohyashiki K. Characteristics of dasatinib - andimatinib-resistant chronic myelogenous leukemia cells. Clin CancerRes 2008; 14: 6181-6186.
37. Hochhaus A, Kreil S, Corbin AS, et al. Molecular andchromosomal mechanisms of resistance to imatinib (STI571)therapy. Leukemia 2002; 16: 2190-2196.
38. Nimmanapalli R, Bhalla K. Mechanisms of resistance to imatinibmesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol 2002;14: 616-620.
39. Mello JV, Chuah C. Resistance to imatinib mesylate in chronicmyeloid leukaemia. Cancer Lett 2007; 249: 121-132.
40. Deininger M, Buchdunger E, Druker BJ. The development ofimatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
41. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABLmutations in patients with CML treated with imatinib is virtuallyalways accompanied by clinical resistance, and mutations in theATP phosphate-binding loop (P-loop) are associated with a poorprognosis. Blood 2003; 102: 276-283.
42. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in latechronic phase chronic myeloid leukemia patients with up-frontcytogenetic resistance to imatinib are associated with a greaterlikelihood of progression to blast crisis and shorter survival: Astudy by the GIMEMA Working Party on Chronic MyeloidLeukemia. J Clin Oncol 2005; 23: 4100-4109.
43. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinicalsignificance of BCR-ABL mutations in patients with chronicmyeloid leukemia treated with imatinib mesylate. Leukemia 2006;20: 1767-1773.
44. Soverini S, Colarossi S, Gnani A, et al. GIMEMA Working Partyon Chronic Myeloid Leukemia. Contribution of ABL kinasedomain mutations to imatinib resistance in different subsets ofPhiladelphiapositive patients: By the GIMEMA Working Party onChronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-7379.
45. La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ.Activity of the Bcr-Abl kinase inhibitor PD180970 againstclinically relevant Bcr-Abl isoforms that cause resistance toimatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-7153.
46. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, GriffinJD. Second generation inhibitors of BCR-ABL for the treatment ofimatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
47. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targetedtherapy in chronic myelogenous leukemia. Semin Hematol 2007;44: S15-24.
48. Gorre ME, Sawyers CL. Molecular mechanisms of resistance toSTI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9:303-307.
49. Hochhaus A. Cytogenetic and molecular mechanisms of resistanceto imatinib. Semin Hematol 2003; 40: 69-79.
50. Ramirez P, Dipersio IF. Therapy options in imatinib failures. Oncologist 2008; 13: 424-434.
51. Thomas J, Wang L, Clark RE et al. Active transport of imatinibinto and out of cells: Implications for drug resistance. Blood 2004;104: 3739-3745.
52. Hegedus T, Orfi L, Seprodi A, et al. Interaction of tyrosine kinaseinhibitors with the human multidrug transporter proteins, MDR1and MRP1. Biochim Biophys Acta 2002; 1587: 318-325.
53. Walz C, Sattler M. Novel targeted therapies to overcome imatinibmesylate resistance in chronic myeloid leukemia (CML). Crit RevOncol Hematol 2006; 57: 145-164.
54. Deininger M. Resistance to imatinib: Mechanisms andmanagement. J Natl Compr Canc Netw 2005; 3: 757-768.
55. Krystal GW. Mechanisms of resistance to imatinib (STI571) andprospects for combination with conventional chemotherapeuticagents. Drug Resist 2001; 4: 16-21.
56. Danhauser-Riedl S, Warmuth M, Druker BJ, et al. Activation ofSrc kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589-3596.
57. Warmuth M, Bergmann M, Priess A, et al. The Src family kinaseHck interacts with Bcr-Abl by a kinase-independent mechanismand phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997; 272: 33260-33270.
58. Roginskaya V, Zuo S, Caudell E, et al. Therapeutic targeting ofSrc-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999;13: 855-861.
59. Lionberger JM, Wilson MB, Smithgall TE. Transformation ofmyeloid leukemia cells to cytokine independence by Bcr-Abl issuppressed by kinasedefective Hck. J Biol Chem 2000; 275:18581-18585.
60. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence andLYN kinase overexpression in chronic myelogenous leukemia cellsselected for resistance to STI571. Blood 2003; 101: 690-698.
61. Dai Y, Rahmani M, Corey SJ, et al. A Bcr/Abl-independent, Lyndependentform of imatinib mesylate (STI-571) resistance isassociated with altered expression of Bcl-2. J Biol Chem 2004;279: 34227-34239.
62. Hu Y, Swerdlow S, Duffy TM, et al. Targeting multiple kinasepathways in leukemic progenitors and stem cells is essential forimproved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870-16875.
63. Meyn MA 3rd, Wilson MB, Abdi FA, et al. Src family kinasesphosphorylate the Bcr- Abl SH3-SH2 region and modulate Bcr-Abltransforming activity. J Biol Chem 2006; 281: 30907-30916.
64. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistancethrough BCR-ABL independence in chronic myelogenousleukemia. Cancer Res 2004; 64: 672-677.
65. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, et al. Clonal Phnegativehematopoiesis in CML after therapy with imatinibmesylate is frequently characterized by trisomy 8. Leukemia 2002;16:1390-1393.
66. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonalcytogenetic abnormalitiesin Ph cells in some CML patients incytogenetic remission to imatinib but restoration of polyclonalhematopoiesis in the majority. Blood 2003; 101:1941-1949.
67. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration ofPhiladelphia chromosome negative abnormal clones in patientswith chronic myelogenous leukemia during major cytogeneticresponses induced by imatinib mesylate. Leukemia 2003; 17: 481-487.
68. Burchert A. Roots of imatinib resistance: A question of selfrenewal? Drug Resist Updat 2007; 10: 152-161.
69. Ogretmen B, Hannun YA. Biologically active sphingolipids incancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604-616.
70. Hannun YA, Obeid LM. The Ceramide-centric universe of lipidmediatedcell regulation: Stress encounters of the lipid kind. J BiolChem 2002; 277: 25847-25850.
71. Merrill AH Jr, Schmelz EM, Dillehay DL, et al. Sphingolipids-theenigmatic lipid class: Biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 1997; 142: 208-225.
72. Futerman AH, Hannun YA. The complex life of simplesphingolipids. EMBO Rep 2004; 5: 777-782.
73. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling andtermination at lipid phosphate receptors. Biochim Biophys Acta 2002; 1582: 121-131.
74. Bektas M, Jolly PS, Müller C, et al. Sphingosine kinase activitycounteracts ceramide-mediated cell death in human melanomacells: Role of Bcl-2 expression. Oncogene 2005; 24: 178-187.
75. Taha TA, Kitatani K, El-Alwani M, et al. Loss of sphingosinekinase-1 activates the intrinsic pathway of programmed cell death:Modulation of sphingolipid levels and the induction of apoptosis. FASEB J 2006; 20: 482-484.
76. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase,sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 2002; 1585: 193-201.
77. Baran Y, Salas A, Senkal CE, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation ofresistance to imatinib-induced apoptosis in K562 human chronicmyeloid leukemia cells. J Biol Chem 2007; 282: 10922-10934.
78. Li Q, Huang WR, Duan HF, et al. Sphingosine kinase-1 mediatesBCR/ABL-induced upregulation of Mcl-1 in chronic myeloidleukemia cells. Oncogene 2007; 26: 7904-7908.
79. Lee SM, Bae JH, Kim MJ, et al. Bcr-Abl-independent imatinibresistantK562 cells show aberrant protein acetylation andincreased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 2007; 322: 1084-1092.
80. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the Cterminus of Ku70 by CBP and PCAF controls Bax-mediatedapoptosis. Mol Cell 2004; 13: 627-638.
81. Kume S, Haneda M, Kanasaki K, et al. Silent information regulator2 (SIRT1) attenuates oxidative stress-induced mesangial cellapoptosis via p53 deacetylation. Free Radic Biol Med 2006; 40:2175-2182.
82. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control ofmultidrug resistance gene mdr1 and cancer resistance tochemotherapy by the longevity gene sirt1. Cancer Res 2005; 65:10183-10187.
83. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl) piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-54825), a dualSrc/Abl kinase inhibitor with potent antitumor activity inpreclinical assays. J Med Chem 2004; 47: 6658-6661.
84. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistancewith a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
85. Haura, E. B.: WO2008089135A2 (2008).
86. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novelaminopyrimidine inhibitor of Bcr-Abl, has in vitro activity againstimatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941-4947.
87. Weisberg E, Manley PW, Breitenstein W, et al. Characterization ofAMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
88. Manley P, von Bubnoff N, Duyster J, et al. AMN107: Inhibitoryprofile against wild-type and mutant forms of the Bcr-Abl tyrosinekinase. 96th Annual Meeting of the American Association forCancer Research. Anaheim (CA) 2005.
89. Sattler M, Mohi MG, Pride YB, et al. Critical role for Gab2 intransformation by BCR-ABL. Cancer Cell 2002; 1: 479-492.
90. O'Hare T, Walters DK, Stoffregen EP, et al. in vitro Activity ofBcr-Abl inhibitors AMN107 and BMS-354825 against clinicallyrelevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4555.
91. Quintás-Cardama A, Kantarjian H, Cortes J. Flying under the radar:The new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834-848.
92. Manley PW, Cowan-Jacob SW, Fendrich G, Metan J. Molecularinteractions between the highly selective pan-Bcr-Abl inhibitor,AMN107, and the tyrosine kinase domain of Abl. Blood 2005; 106:940a.
93. O'Hare T, Walters DK, Stoffregen EP, et al. in vitro Activity ofBcr-Abl inhibitors AMN107 and BMS-354825 against clinicallyrelevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4505.
94. Weisberg E, Manley PW, Breitenstein W, et al. Characterization ofAMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
95. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP competitive inhibitor of Bcr-Abl overrides imatinib resistance. Proc Natl Acad Sci USA 2005; 102: 1992-1997
96. Giet R, Prigent C. Aurora/Ipl1p-related kinases, a new oncogenicfamily of mitotic serine-threonine kinases. J Cell Sci 1999;112:3591-3601.
97. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potentand selective small-molecule inhibitor of the Aurora kinases,suppresses tumor growth in vivo. Nat Med 2004; 10: 262-267.
98. Young MA, Shah NP, Chao LH, et al. Structure of the kinasedomain of an imatinib-resistant Abl mutant in complex with theAurora kinase inhibitor VX-680. Cancer Res 2006; 66: 1007-1014.
99. Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinaseinhibitor, is active in patients with chronic myeloid leukemia oracute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500-502.
100. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drugresistantmutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102:11011-11016.
101. O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I)inhibitor. Nat Biotechnol 2005; 23: 1209-1210.
102. Burley SK. Application of FASTTM fragment-based leaddiscovery and structure-guided design to discovery of smallmolecule inhibitors of BCR-ABL tyrosine kinase active against T315I imanitib-resistant mutant (abstract 698). Blood 2005; 106:11 (Suppl) 206a.
103. Thurston DE, Bose DS. Synthesis of DNA-interactive pyrrolo-[2,1c][1,4]benzodiazepines. Chem Rev 1994; 94: 433-465.
104. Tada-Oikawa S, Oikawa S, Kawanishi M, Yamada M, Kawanishi S. Generation of hydrogen peroxide precedes loss of mitochondrialmembrane potential during DNA alkylation-induced apoptosis. FEBS Lett 1999; 442: 65-69.
105. Rotas G, Natchkebia K, Natsvlishvili N, et al. Action of a novelpyrrolo[1,2-c]-[1,3]benzodiazepine on the viability of Jurkat andneuronal/glial cells. Bioorg Med Chem Lett 2005; 15: 3220-3223.
106. Artico M, Silvestri R, Pagnozzi E, et al. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A novel class of non-nucleosidereverse transcriptase inhibitors. Bioorg Med Chem 1996; 4: 837-850.
107. Chimenti F, Vomero S, Nacci V, et al. Research on compoundswith antiblastic activity. LVII. Anthramycin and related compounds.VI. Synthesis of pyrrolo[1,2-b][1,2,5]-benzothiadiazepinederivatives. Farmaco 1974; 29: 589-597.
108. Picte A, Spengler T. Formation of isoquinoline derivatives by theaction of methylal on phenylethylamine, phenylalanine andtyrosine. Chem Ber 1911; 44: 2030-2036.
109. Silvestri R, Marfè G, Artico M, et al. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with highapoptotic activity in chronic myelogenous leukemia K562 cells andin cells from patients at onset and who were imatinib-resistant. JMed Chem 2006; 49: 5840-5844.
110. Marfe G, Di Stefano C, Silvestri R, et al. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) induce apoptosis in K562 cells. BMC Cancer 2007; 7: 207.
111. Otahalova, E., Lebowitz, M., Ghanbari, H. A.: US20080124718A1 (2008).
112. Wedge, St. R.: US20080015205A1 (2008).
113. Thomas, D. A.: US20090028933A1 (2009).
114. Silvestri, R., Marfe', G., Abruzzese, E., Catalano, G., Di Stefano, C., Novellino, E., Sinibaldi Salimei, P., De Martino, M. G., LaRegina, G., Lavecchia, A.: WO2007015280A1 (2007).